HY-004 (Juventas)

N/A

Report date: 2026/05/12 20:00:17

Base Information

Drug NameHY-004 (Juventas)
Drug Alias NameHY-004 (Juventas)
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionAnti-CD19Anti-CD22
TargetsB-lymphocyte antigen CD19CD22
Therapy Area/IndicationsLymphoma, Non-HodgkinPrecursor B-Cell Lymphoblastic Leukemia-LymphomaPrecursor Cell Lymphoblastic Leukemia-Lymphoma +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesJuventas Cell Therapy Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesJuventas Cell Therapy Ltd
Inactive CompaniesN/A
Active IndicationsLymphoma, Non-HodgkinPrecursor Cell Lymphoblastic Leukemia-LymphomaLeukemia, B-Cell
Inactive IndicationsPrecursor B-Cell Lymphoblastic Leukemia-Lymphoma

Other Information

ATC CodeN/A
Related LinksN/A